Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and ...
As a hepatologist, Aleksander Krag has always sought to improve the prognosis of patients with liver disease, whom, he tells The Lancet, he often thinks of as a fictional patient he calls “Henry”. His ...
Global MASH cirrhosis burden is rapidly increasing, yet therapeutic and prognostic frameworks remain limited, with sparse ...
Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and ...
Please provide your email address to receive an email when new articles are posted on . Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression.
Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) is a potent vasodilator and immunoregulator. This study aimed to explore ...
Use of sodium-glucose cotransporter-2 inhibitors was linked to significantly reduced risk for adverse kidney, cardiovascular and hepatic outcomes in patients with type 2 diabetes and cirrhosis, ...
Despite combination prophylaxis with HBIG and NUCs transforming outcomes after liver transplantation for hepatitis B, some ...
Cirrhosis is permanent damage to the liver that happens from long-term illness. It can lead to liver failure or cancer, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results